AAR	Austrian Azacitidine Registry
AE	Adverse event
AGMT	Arbeitsgemeinschaft Medikamentöse Tumortherapie
AHRQ	Agency for Healthcare Research and Quality
AML	Acute myeloid leukaemia
ANC	Absolute neutrophil count
AZA	Azacitidine
BM	Bone marrow
BSC	Best supportive care
CI	Confidence interval
CMML	Chronic myelomonocytic leukaemia
CR	Complete response
CRi	Morphologic CR with incomplete blood count recovery
ECOG-PS	Eastern Cooperative Oncology Group Performance Status
eCRF	Electronic case report form
EFS	Event-free survival
EMA	European Medicines Agency
HSCT	Hematopoietic stem cell transplantation
Hb	Haemoglobin
HR	Hazards ratio
IWG	International Working Group
KM	Kaplan–Meier
MDS	Myelodysplastic syndromes
MPN	Myeloproliferative neoplasm
MRC	Myelodysplasia-related changes
NCCN	National Comprehensive Cancer Network
NOS	Not otherwise specified
ORR	Overall response rate
OS	Overall survival
PLT	Platelet
PR	Partial response
pts	Patients
RBC	Red blood cell
RCA	Recurrent cytogenetic abnormalities
RFS	Relapse-free survival
SD	Standard deviation
t-AML	Therapy-related AML
TD	Transfusion dependence
TEAE	Treatment-emergent adverse event
TI	Transfusion independence
vs.	Versus
WBC	White blood cell
WHO	World Health Organisation